 SHANGHAI and HONG KONG , July 13, 2021 PRNewswire -- Antengene Corporation Limited Antengene, SEHK: 6996.HK, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class andor best-in-class therapeutics in hematology and oncology, today announced that it has submitted a New Drug Application NDA to the Taiwan Food and Drug Administration TFDA for selinexor, a first-in-class XPO1 inhibitor, for three indications: in combination with bortezomib and dexamethasone XVd, or in combination with dexamethasone Xd for the treatment of patients with relapsed andor refractory multiple myeloma RRMM; and as monotherapy in adult patients with relapsed andor refractory diffuse large B-cell lymphoma rrDLBCL, including DLBCL arising from follicular lymphoma, who have received at least two lines of systemic therapy. Antengene has submitted New Drug Applications NDAs for selinexor in multiple Asia Pacific markets including China, Australia, South Korea, and Singapore, and was granted Priority Review status by Chinas National Medical Products Administration NMPA and Orphan Drug Designation by the Ministry of Food and Drug Safety of South Korea MFDS. 